DOCSLIB.ORG

Brinzolamide/Timolol 10Mg/Ml + 5Mg/Ml Eye Drops, Suspension

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Brinzolamide/Timolol 10Mg/Ml + 5Mg/Ml Eye Drops, Suspension Package leaflet: Information for the user Brinzolamide/Timolol 10mg/ml + 5mg/ml eye drops, suspension Read all of this leaflet carefully Other medicines and before you start using this Brinzolamide/Timolol eye drops medicine because it contains Tell your doctor or pharmacist if you are using, have recently used or might important information for you. use any other medicines. - Keep this leaflet. You may need Brinzolamide/Timolol eye drops can affect, or be affected by, other to read it again medicines you are taking, including - If you have any further questions, other eye drops for the treatment ask your doctor, pharmacist or of glaucoma. Tell your doctor if nurse you are taking or intend to take medicines to lower blood pressure - This medicine has been like parasympathomimetics and prescribed for you only. Do not guanetidine, or other heart medicines pass it on to others. It may harm including quinidine (used to treat heart them, even if their signs of illness conditions and some types of malaria), are the same as yours amiodarone or other medicines to treat heart rhythm disorders and glycosides - If you get any side effects, talk to to treat heart insufficiency. Also tell your doctor or pharmacist. This your doctor if you are taking or intend includes any possible side effects to take medicines to treat diabetes, not listed in this leaflet. See or to treat gastric ulcers, antifungal, antiviral or antibiotic medicines, or section 4 antidepressants such as fluoxetine and - The full name of this medicine is paroxetine. Brinzolamide/Timolol If you are taking another carbonic 10mg/mL + 5mg/mL eye drops, anhydrase inhibitor (acetazolamide or suspension but within this dorzolamide), talk to your doctor. leaflet it will be referred to as Increase in pupil size when taking Brinzolamide/Timolol eye drops. Brinzolamide/Timolol eye drops and adrenaline (epinephrine) together has What is in this leaflet been reported occasionally. 1 What Brinzolamide/Timolol Pregnancy and breast-feeding eye drops are and what they You should not use Brinzolamide/ are used for Timolol eye drops if you are pregnant 2 or might get pregnant, unless What you need to know your doctor considers it necessary. before you use Brinzolamide/ Talk to your doctor before you use Timolol eye drops Brinzolamide/Timolol eye drops. 3 How to use Brinzolamide/ Do not use Brinzolamide/Timolol eye Timolol eye drops drops if you are breast-feeding, timolol 4 Possible side effects may get into your milk. 5 How to store Brinzolamide/ Ask your doctor for advice before taking any medicine during breast- Timolol eye drops feeding. 6 Contents of the pack and other information Driving and using machines 1 Do not drive or use machines until What Brinzolamide/Timolol your vision is clear. You may find that eye drops are and what they your vision is blurred for some time just are used for after using Brinzolamide/Timolol eye drops. Brinzolamide/Timolol eye drops contain two active substances, One of the active ingredients may brinzolamide and timolol, which work impair the ability to perform tasks together to reduce pressure within the requiring mental alertness and/or eye. physical coordination. If affected take care when driving or using machines. Brinzolamide/Timolol eye drops are used to treat high pressure in the Brinzolamide/Timolol eye drops eyes, also called glaucoma or ocular contains benzalkonium chloride hypertension, in adult patients that are more than 18 years of age and This medicine contains 0.0033mg in whom high pressure in the eyes benzalkonium chloride in each drop cannot be controlled effectively by one which is equivalent to 0.01% or medicine alone. 0.1mg/ml. Benzalkonium chloride is a 2 What you need to know preservative in Brinzolamide/Timolol before you use Brinzolamide/ eye drops that may be absorbed by Timolol eye drops soft contact lenses and may change the colour of the contact lenses. You Do not use Brinzolamide/Timolol should remove contact lenses before eye drops if you: using this medicine and put them back - are allergic to brinzolamide, 15 minutes afterwards. medicines called sulphonamides Benzalkonium chloride may also cause (examples include medicines used eye irritation, especially if you have to treat diabetes, infections and also dry eyes or disorders of the cornea diuretics (water tablets)), timolol, (the clear layer at the front of the eye). beta-blockers (medicines used to If you feel abnormal eye sensation, lower blood pressure or to treat stinging or pain in the eye after using heart disease) or any of the other this medicine, talk to your doctor. ingredients of this medicine (listed in section 6) 3 How to use Brinzolamide/ - have now or have had in the past Timolol eye drops respiratory problems such as asthma, severe long lasting obstructive Always use this medicine exactly as bronchitis (a severe lung condition your doctor or pharmacist has told you. which may cause wheezing, difficulty Check with your doctor or pharmacist in breathing and/or long standing if you are not sure. cough) or other types of breathing If you are changing from another eye problems drop medicine used to treat glaucoma - have severe hay fever to Brinzolamide/Timolol eye drops, you - have a slow heartbeat, heart failure or should stop using the other medicine disorders of heart rhythm (irregular and start using Brinzolamide/Timolol heartbeats) eye drops the following day. Check - have too much acidity in your blood with your doctor or pharmacist if you (a condition called hyperchloraemic are not sure. acidosis) - have severe kidney problems. To prevent contamination of the dropper tip and the suspension, care Warnings and precautions must be taken not to touch the eyelids, surrounding areas, or other surfaces Only use Brinzolamide/Timolol eye with the dropper tip. Keep the bottle drops for dropping in your eye(s). tightly closed when not in use. If signs of serious reactions or The following measure is useful to limit hypersensitivity occur, discontinue the the amount of medicine that will come use of this product and talk to your into the blood after application of eye doctor. drops: - Keep the eyelid closed, while Talk to your doctor, pharmacist or simultaneously applying gentle nurse before using Brinzolamide/ pressure to the corner of the eye next Timolol eye drops if you have or have to the nose with a finger for at least 2 had in the past: minutes. - coronary heart disease (symptoms can include chest pain or tightness, The recommended dose is one drop breathlessness or choking), heart in the affected eye or eyes, twice a day. failure, low blood pressure Only use Brinzolamide/Timolol eye - disturbances of heart rate such as drops in both eyes if your doctor slow heart beat told you to. Take it for as long as your - breathing problems, asthma or doctor told you to. chronic obstructive pulmonary disease How to use - poor blood circulation disease (such as Raynaud’s disease or Raynaud’s syndrome) - diabetes as timolol may mask signs and symptoms of low blood sugar - overactivity of the thyroid gland as timolol may mask signs and symptoms of thyroid disease - muscular weakness (myasthenia gravis) - tell your doctor before you have an operation that you are using Brinzolamide/Timolol eye drops 1 as timolol may change the effects of some medicines used during anaesthesia - have a history of atopy (a tendency to develop an allergic reaction) and severe allergic reactions you may be more sensitive to developing an allergic reaction whilst using Brinzolamide/Timolol eye drops and adrenaline may not be as effective to treat an allergic reaction. When receiving any other treatment please tell the doctor or nurse that you are taking Brinzolamide/Timolol eye 2 drops - have liver problems - have dry eyes or cornea problems - have problems with your kidneys. Children and adolescents Brinzolamide/Timolol eye drops are not recommended for children and adolescents under 18 years. 3 continued top of next column BBBA7130 continued over page Brinzolamide/Timolol 10 mg/ml Eye drops, suspension 1 x 5ml PIL - UK approved for print/date Item number: BBBA7130 Colours Non Printing Colours 1. Black 1. Originator: G. Worth Dimensions: 140x590 Origination Date: 13/12/2019 Min Body Text Size: 9pt 2. 2. Revision Date: 19/12/2019 Supplier: Lusomedicamenta 3. 3. Revised By: G. Worth (Recipharm Lisbon) 4. 5. Proof Round 13/12/2019 Technical Date sent: 6. 4 Approval Date received: 07/01/2020 [email protected] Cartons and label leaflets only (labels only when specified) GTIN 13 (Belgium & Slovenia): German GTIN 14 (incorporating PZN): * Please note that only Artwork Studio is permitted to make changes to the above artwork. Version 6 No changes are permitted by any 3rd party other than added notes and mark ups for required changes. 12.12.2019 - Get the bottle and a mirror - Respiratory: Constriction of the - Wash your hands airways in the lungs (predominantly - Shake well before use in patients with pre-existing disease) - Twist off the bottle cap. After the cap shortness of breath or difficulty is removed, if the tamper evident breathing, cold symptoms, chest snap collar is loose, remove before congestion, sinus infection, sneezing, using product stuffy nose, dry nose, nose bleeds, - Hold the bottle, pointing down, asthma, throat irritation. between your thumb and forefinger - Nervous system and general - Tilt your head back. Pull down your disorders: depression, nightmares, eyelid with a clean finger, until there memory loss, headache, nervousness, is a ‘pocket’ between the eyelid and irritability, tiredness, shaking, your eye. The drop will go in here feeling abnormal, fainting, dizziness, (picture 1) drowsiness, generalised or severe - Bring the bottle tip close to the eye. weakness, unusual sensations like Use the mirror if it helps pins and needles, hallucinations.
Load more

Recommended publications
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • AZARGA, INN-Brinzolamide/Timolol
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT AZARGA 10 mg/ml + 5 mg/ml eye drops, suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of suspension contains 10 mg brinzolamide and 5 mg timolol (as timolol maleate). Excipient with known effect: One ml of suspension contains 0.10 mg benzalkonium chloride. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Eye drops, suspension (eye drops) White to off-white uniform suspension, pH 7.2 (approximately). 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction (see section 5.1). 4.2 Posology and method of administration Posology Use in adults, including the elderly The dose is one drop of AZARGA in the conjunctival sac of the affected eye(s) twice daily. When using nasolacrimal occlusion or closing the eyelids, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity (see section 4.4). If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye (s) twice daily. When substituting another ophthalmic antiglaucoma medicinal product with AZARGA, the other medicinal product should be discontinued and AZARGA should be started the following day. Special populations Paediatric population The safety and efficacy of AZARGA in children and adolescents aged 0 to 18 years have not yet been established.
    [Show full text]
  • WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/066775 Al 1 May 2014 (01.05.2014) W P O PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61F 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/066834 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 25 October 2013 (25.10.201 3) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/719,144 26 October 2012 (26. 10.2012) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: FORSIGHT VISION5, INC. [US/US]; 191 kind of regional protection available): ARIPO (BW, GH, Jefferson Drive, Menlo Park, CA 94025 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: RUBIN, Anne, Brody; 191 Jefferson Drive, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Menlo Park, CA 94025 (US).
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Latanoprost Ophthalmic Emulsion
    Contains Nonbinding Recommendations Draft Guidance on Latanoprost This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Latanoprost Dosage Form; Route: Emulsion; ophthalmic Strength: 0.005% Recommended Study: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.005% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes Additional comments: Specific recommendations are provided below Analyte s to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference standard (RS) product, each applied as one drop in both eyes once daily in the evening for 42 days (6 weeks). 2. Inclusion criteria (the applicant may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes. b. Subject requires treatment of both eyes and is able to discontinue use of all ocular hypotensive medication(s) or switch ocular hypotensive medications and undergo appropriate washout period.
    [Show full text]
  • AZARGA® Eye Drops Brinzolamide 10 Mg/Ml and Timolol 5 Mg/Ml CONSUMER MEDICINE INFORMATION
    AZARGA® Eye Drops Brinzolamide 10 mg/mL and timolol 5 mg/mL CONSUMER MEDICINE INFORMATION What Is In This Leaflet Although AZARGA helps control your glaucoma, it does not cure it. Please read this leaflet carefully For more information about before you use any AZARGA Eye What AZARGA is used glaucoma, contact Glaucoma drops. for Australia on 1800 500 880 or Glaucoma New Zealand on 09 373 This leaflet answers some common AZARGA is used to lower pressure 8779. questions about AZARGA. It does in the eye and to treat glaucoma. not contain all of the available Glaucoma is a condition in which the Your doctor may have prescribed information. It does not take the pressure of fluid in the eye may be AZARGA for another reason. Ask place of talking to your doctor or high. However, some people with your doctor if you have any questions pharmacist. glaucoma may have normal eye about why AZARGA has been The information in this leaflet was pressure. prescribed for you. last updated on the date listed on the Glaucoma is usually caused by a There is no evidence that AZARGA final page. More recent information build-up of the fluid which flows is addictive. on the medicine may be available. through the eye. This build up occurs You should ensure that you speak because the fluid drains out of your Use in Children to your pharmacist or doctor to eye more slowly than it is being There is not enough information to obtain the most up to date pumped in. Since new fluid continues recommend the use of this medicine information on the medicine.
    [Show full text]
  • Safety and Efficacy of SIMBRINZA BID As an Adjunctive to DUOTRAV
    Alcon - Business Use Only Protocol - Clinical Effective Date: 10-Apr-2017 Document: TDOC-0051572 Version: 2.0; Most-Recent; Effective; CURRENT Status: Effective Page 1 of 71 a Novartis company Short Title Safety and Efficacy of SIMBRINZA BID as an Adjunctive to DUOTRAV Long Title Safety and Efficacy with Twice Daily Brinzolamide 1% / Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004% / Timolol 0.5% (DUOTRAV) Protocol Number: GLJ576-P001/ NCT02730871 Study Phase: 4 Sponsor Name and Alcon Research, Ltd. Address: 6201 South Freeway Fort Worth, Texas 76134-2099 Investigational Product: SIMBRINZA Brinzolamide 1% (10 mg/mL)/Brimonidine 0.2% (2 mg/mL) eye drops suspension US IND# / EudraCT 2016-000176-20 Indication Studied: Ocular Hypertension Open Angle Glaucoma Printed By: Print Date: Alcon - Business Use Only Protocol - Clinical Effective Date: 10-Apr-2017 Document: TDOC-0051572 Version: 2.0; Most-Recent; Effective; CURRENT Status: Effective Page 2 of 71 Investigator Agreement: I have read the clinical study described herein, recognize its confidentiality, and agree to conduct the described trial in compliance with Good Clinical Practices (GCP), the ethical principles contained within the Declaration of Helsinki, this protocol, and all applicable regulatory requirements. Additionally, I will comply with all procedures for data recording and reporting, will permit monitoring, auditing, and inspection of my research center, and will retain all records until notified by the Sponsor. Principal Investigator: Signature Date Name: Address: Printed By: Print Date: Alcon - Business Use Only Protocol - Clinical Effective Date: 10-Apr-2017 Document: TDOC-0051572 Version: 2.0; Most-Recent; Effective; CURRENT Status: Effective Page 3 of 71 1 SYNOPSIS Sponsor: Alcon Research, Ltd.
    [Show full text]
  • Drugs That May Be Used Based on Licensure Designation Page 1 of 7 Updated February 2021 by the Pennsylvania State Board of Optometry
    Drugs Which May Be Used Based on Licensure Designation Approved Drugs a.) Administration and prescription of pharmaceutical agents for therapeutic purposes. Optometrists who are certified to prescribe and administer pharmaceutical agents for therapeutic purposes under section 4.1 of the Optometric Practice and Licensure Act (63 P. S. § 244.4a), may prescribe and administer the drugs listed in subsections (c)(1) – (11) below in their practice of optometry. See also 49 Pa. Code § 23.202 for the application procedure for optometrists to administer and prescribe pharmaceutical agents for therapeutic purposes. b.) Administration and prescription of pharmaceutical agents to treat glaucoma. Optometrists who are certified to prescribe and administer pharmaceutical agents to treat glaucoma under section 4.2 of the Optometric Practice and Licensure Act (63 P.S. § 244.4b), may prescribe and administer the drugs listed in subsection (c)(12) below in their practice of optometry. See also 49 Pa. Code § 23.205 for the application procedure for optometrists to administer and prescribe pharmaceutical agents to treat glaucoma. c.) DEA registration reminder. Licensees who hold, or plan to obtain, a DEA registration are reminded to review and comply with PDMP standards. d.) Allowable pharmaceutical products. Optometrists may prescribe and administer the following pharmaceutical products or the A-rated generic therapeutically equivalent drug: (1) Topical Anesthetics (i) benoxinate (ii) lidocaine (iii) proparacaine (iv) tetracaine (2) Topical Ocular Lubricants
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Glaucoma Drugs
    Top 5 Ophthalmology Peer Reviewed TOP 5 Glaucoma Drugs Erin M. Scott, VMD, & Gillian J. McLellan, BVMS, PhD, DVOphthal, DECVO, DACVO, MRCVS University of Wisconsin –Madison laucoma is typically associated with elevated intraocular pres - sure (IOP) resulting from impaired aqueous humor outflow and leads to irreversible damage to the optic nerve and G TOP 5 GLAUCOMA DRUGS retina. 1,2 Primary glaucomas are relatively common and have strong breed predilections in dogs but are rarely diagnosed in cats. 1,3,4 Sec - ondary glaucomas are as frequent as primary glaucomas in dogs and 1. Carbonic anhydrase inhibitors constitute 95% to 98% of glaucoma cases in cats. 1,4-7 They are usually 2. Prostaglandin analogs secondary to an ocular or systemic disorder that impairs aqueous humor outflow (eg, uveitis, neoplasia, lens luxation, trauma). 8 Since 3. β-blockers glaucomas are heterogeneous in terms of pathogenesis, therapy must 4. Miotics be tailored to each patient (see Commonly Used Glaucoma Drugs at a Glance , next page ). Glaucoma medications target IOP by either 5. Hyperosmotic agents decreasing production or increasing outflow of aqueous humor. Carbonic Anhydrase Inhibitors Carbonic anhydrase, an enzyme present in the ciliary body epithelium, contributes to Glaucoma medications aqueous humor production. Carbonic anhydrase inhibitors (CAIs) can decrease aque - 1 ous humor production in dogs and cats by over 40%. 9,10 Dorzolamide 2% effectively target IOP by either lowers IOP when administered q8h. 10-13 It may be used in the management of acute decreasing production glaucomatous crises and for long-term control of IOP. Dorzolamide may be considered a safe first-line drug of choice for dogs and cats with glaucoma, regardless of cause.
    [Show full text]
  • Azarga (Brinzolamide and Timolol Maleate) Eye Drops
    AUSTRALIAN PRODUCT INFORMATION – AZARGA (BRINZOLAMIDE AND TIMOLOL MALEATE) EYE DROPS 1 NAME OF THE MEDICINE Brinzolamide and timolol maleate. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of AZARGA Eye Drops suspension contains brinzolamide 10 mg (1%) and timolol 5 mg (0.5%) (as timolol maleate). The pH of AZARGA is approximately 7.2. May contain traces of potential allergens such as benzoates, sulfites and hydroxybenzoates from the manufacturing process. For the full list of excipients, see Section 6.1 List of excipients. 3 PHARMACEUTICAL FORM Eye drops. AZARGA is a white to off-white uniform suspension. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension for whom monotherapy with either component provides insufficient IOP reduction. 4.2 DOSE AND METHOD OF ADMINISTRATION The recommended dosage is one drop of AZARGA in the conjunctival sac of the affected eye(s) twice daily. Shake the bottle well before use. Nasolacrimal occlusion and gently closing the eyelid after instillation are recommended. This may reduce the systemic absorption of eye drops and result in a decrease in systemic adverse reactions. If more than one topical ophthalmic medicine is being used, the medicines must be administered at least 5 minutes apart. If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) twice daily. When substituting another ophthalmic antiglaucoma agent with AZARGA, the other agent should be discontinued and AZARGA should be started the following day. To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle.
    [Show full text]
  • Brinzolamide/ Timolol Mylan 10 Mg/Ml + 5 Mg/Ml Eye Drops
    Package leaflet: Information for for the treatment of glaucoma. Tell your the user doctor if you are taking or intend to take medicines to lower blood pressure like Brinzolamide/ parasympathomimetics and guanetidine, or other heart medicines including Timolol Mylan quinidine (used to treat heart conditions and some types of malaria), amiodarone 10 mg/ml + 5 mg/ml or other medicines to treat heart rhythm disorders and glycosides to treat heart eye drops, insufficiency. Also tell your doctor if you are taking or intend to take medicines suspension to treat diabetes, or to treat gastric brinzolamide/timolol ulcers, antifungal, antiviral or antibiotic medicines, or antidepressants such as Read all of this leaflet carefully fluoxetine and paroxetine. before you start using this medicine because it contains important If you are taking another carbonic information for you. anhydrase inhibitor (acetazolamide or dorzolamide), talk to your doctor. • Keep this leaflet. You may need to Increase in pupil size when taking read it again. Brinzolamide/Timolol Mylan and • If you have any further questions, ask your doctor or pharmacist. adrenaline (epinephrine) together has • This medicine has been prescribed been reported occasionally. for you only. Do not pass it on to Pregnancy and breast-feeding others. It may harm them even if You should not use Brinzolamide/Timolol their signs of illnesses are the same Mylan if you are pregnant or might get as yours. pregnant, unless your doctor considers it • If you get any side effects, talk to necessary. Talk to your doctor before you your doctor or pharmacist. This includes any possible side effects not use Brinzolamide/Timolol Mylan.
    [Show full text]